Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Calliditas Therapeutics’ 2021 Annual Report Published

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2021 now is available at the company’s website: www.calliditas.com. This information is information that Calliditas Therapeutics AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 18:00 CET on April 27, 2022. For further information, please contact: Marie Galay, IR Manager, Calliditas Tel.: +44 79 55 12 98 45, email: marie.galay@calliditas.com About Calliditas Calliditas Therapeutics is a commercial

Endomines Annual Report 2021 now published

Endomines AB, stock exchange release 27 April 2022 at 18:00 CEST   Endomines AB’s Annual Report in Swedish for 2021 in pdf-format and European Single Electronic Format (ESEF) is available on the Company’s website www.endomines.com   For further information, please contact: Kari Vyhtinen, CEO, kari.vyhtinen@endomines.com, +358 40 585 0050   This information is information that Endomines AB is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication through the contact person set out above, at 18:00 CEST on 27 April

Scandion Oncology Announces Results of Annual General Meeting and Constitution of the Board of Directors

The Annual General Meeting 2022 of Scandion Oncology A/S (the "Company") was held on 27 April 2022 at 4:00 p.m.All proposals were adopted in accordance with the notice. Immediately after the general meeting, the board of directors constituted itself with Martin Møller as chairman and Jørgen Bardenfleth as deputy chairman. The full minutes of the annual general meeting are attached to this notice. The agenda of the annual general meeting was as follows: 1. Election of chairman of the meeting 2. Report from the board of directors on the Company's activities in the pastyear

Business transacted at the annual general meeting of Aquaporin A/S

Kgs. Lyngby, Denmark, 27 April 2022, Aquaporin A/S, CVR no. 28 31 56 94 (the “Company”) today held its annual general meeting, at which the general meeting: · took note of the Board of Directors’ report on the Company’s activities in the past financial year; · adopted the annual report for 2021; · adopted the Board of Director’s proposal to carry forward the loss of the financial year ended 31 December 2021 and that no divided is paid to shareholders for the financial year ended 31 December 2021; · resolved to grant discharge of liability to the Board of Directors and the

CLS receives approximately SEK 12.2 million through the exercise of subscription warrants of series TO3

Clinical Laserthermia Systems AB (publ) (“CLS” or the “Company”) carried out a rights issue of units (the “Rights Issue”) and a directed issue of units (the “Directed Issue”) in April 2021. The units issued in the Rights Issue and the Directed Share Issue consisted of shares and subscription warrants from the TO3 (the “Subscription Warrants”) and TO4 series. The exercise period for the TO3 subscription warrants ran during the period from April 11, 2022 until April 25, 2022. In total, 3,484,241 Subscription Warrants were exercised for subscription of new class B shares, corresponding to an

Invitation to Tobii’s webcast following the interim report for the first quarter report of 2022

Tobii AB (publ) plans to publish the interim report for the period January 1-March 31, 2022 on May 5 at 7.30 a.m. CET. Following this report, at 9.00 a.m. CET, Tobii will host a presentation for investors, analysts and media. Tobii’s President and CEO Anand Srivatsa and CFO Magdalena Rodell Andersson will present and comment on the report. After the presentation, there will be time for questions. The presentation will be held in English. Details · Time: Thursday May 5, 2022, 9.00 a.m. CET · Webcast: Link to the webcast 

UNITED BANKERS PLC: ACQUISITION OF OWN SHARES 27.04.2022

United Bankers Plc NOTIFICATION   27.04.2022 at 18:30   UNITED BANKERS PLC: ACQUISITION OF OWN SHARES 27.04.2022   Date 27.04.2022  Exchange transaction Buy  Share class UNITED  Amount 350  Average price/share 13.4000 EURHighest price/share 13.4000 EURLowest price/share 13.4000 EURTotal price 4,690.00 EUR        The shares held by United Bankers Plc on 27.04.2022:   UNITED 54,997         On behalf of United

FISKARS CORPORATION: ACQUISITION OF OWN SHARES 27.04.2022

Fiskars Corporation   Stock Exchange Release 27.04.2022 at 18:30 EET/EEST   FISKARS CORPORATION: ACQUISITION OF OWN SHARES 27.04.2022   Date 27.04.2022  Exchange transaction Buy  Share class FSKRS  Amount  4,500  Average price/share 20.2122 EURHighest price/share 20.3500 EURLowest price/share 20.0000 EURTotal price 90,954.90 EUR        The shares held by Fiskars Corporation on 27.04.2022:   FSKRS 543 135       On

CLS tillförs cirka 12,2 MSEK genom utnyttjandet av teckningsoptioner av serie TO3

Clinical Laserthermia Systems AB (publ) (“CLS” eller “Bolaget”) genomförde under april 2021 en företrädesemission av units (”Företrädesemissionen”) samt en riktad emission av units (”Riktade emissionen”). De units som emitterades i Företrädesemissionen och den Riktade emissionen bestod av aktier och teckningsoptioner av serie TO3 (”teckningsoptionerna”) och TO4. Utnyttjandeperioden för teckningsoptionerna av serie TO3 pågick under perioden från och med den 11 april 2022 till och med den 25 april 2022. Totalt utnyttjades 3 484 241 teckningsoptioner för teckning av nya B-aktier, motsvarande en

Communique from annual general meeting in Mentice AB

Press release 2022-04-27An annual general meeting was held in Mentice AB on 27 April 2022. Below follows a summary of the resolutions made at the meeting. Adoption of the income statement and the balance sheet, the consolidated income statement and the consolidated balance sheet and discharge from liability At the annual general meeting the income statement and the balance sheet, the consolidated income statement and the consolidated balance sheet for 2021 were adopted. The meeting resolved to discharge each member of the board of directors alongside with the CEO from liability for

Report from Annual General Meeting of Vitrolife AB (publ)

At Vitrolife’s Annual General Meeting today, the following, amongst other things, was decided:• Resolution in accordance with the Board’s proposed dividend of SEK 0.80 per share for the financial year 2021. Friday April 29, 2022 was adopted as the record day.• Re-election of Board members Henrik Blomquist, Lars Holmqvist, Vesa Koskinen, Pia Marions, Jón Sigurdsson and Karen Lykke Sørensen, in accordance with the election committee’s proposal. Jón Sigurdsson was re-elected Chairman of the Board.• Remuneration to the members of the Board shall be totaling SEK 3,600,000, of which SEK 1,

#22-145 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a

Tradedoubler Annual Report 2021 published

Tradedoubler has as of today published the Annual report 2021. The Annual Report is prepared in Swedish and translated into English. Both versions are available at Tradedoubler’s website. Please find the English version by clicking the following link: https://www.tradedoubler.com/en/investors/financial-information-and-publications/ For further information, please contact: Matthias Stadelmeyer, CEO TradedoublerPhone: +46 8 405 08 00Email: ir@tradedoubler.com About this information This information is information that Tradedoubler AB is obliged to make public pursuant to

Resolutions at ASSA ABLOY AB’s Annual General Meeting 27 April 2022

The Annual General Meeting of ASSA ABLOY AB was held on Wednesday 27 April 2022 in Stockholm, Sweden. Adoption of income statements and balance sheets and discharge from liability The Annual General Meeting adopted the parent company’s and the Group’s income statements and balance sheets for the financial year 2021. The members of the Board of Directors and the CEO were discharged from liability for the financial year 2021. Dividend  The Annual General Meeting approved the dividend of SEK 4.20 per share proposed by the Board of Directors, to be paid out in two equal installments,

Bulletin from the AGM of Troax Group AB (publ)

Hillerstorp April 27[th], 2022 16:30 CETThe AGM of Troax Group AB (publ) was held on April 27[th], 2022 in Hillerstorp. Adoption of the Income Statements and Balance Sheets, dividend and discharge of liabilityThe Income Statements and Balance Sheets were adopted, together with the Board of Directors` proposal for dealing with the Company ́s profit. The dividend was set at 0,3 Euro per share with April 29[th] as the record day. The estimated date for payment is May 6[th] , 2022. The Board of Directors and the President were discharged from liability for the financial year 2021.

Bulletin from the Annual General Meeting of Formpipe Software AB held 27 April 2022

Allocation of the company’s results and discharge from liability The Annual General Meeting (AGM) resolved, in accordance with the Board of Directors’ proposal, that SEK 0.70 per share shall be paid in dividend to the shareholders for the financial year 2021 and that the record date for the dividend shall be 29 April 2022. The dividend is expected to be distributed by Euroclear Sweden AB on 4 May 2022. The members of the Board of Directors and the CEO were discharged from liability for the financial year 2021. Election of Board members, Chairperson of the Board, auditor and

Issue and repurchase of class C shares for incentive programs

The board of directors of Tobii AB (publ) (“Tobii”) today resolved to issue 759,345 new class C shares and to immediately thereafter repurchase the 759,345 newly issued class C shares. Today’s resolution by the board of directors was passed based on the authorization granted by the extraordinary general meeting held on 25 October 2021. Aktieinvest FK AB will subscribe for all issued class C shares at a subscription price corresponding to the quota value of approximately SEK 0.007 per share and Tobii will repurchase all issued C-shares at a purchase price corresponding to the quota value

ANNOUNCEMENT FROM SOTKAMO SILVER AB AGM ON APRIL 27, 2022

Press release: Stockholm, April 27, 2022, 16:15 CET Sotkamo Silver AB (publ) held its Annual General Meeting (AGM) on 27 April 2022. Due to the ongoing Covid-19 situation, the AGM was held only by a postal voting procedure with the support of temporary legal rules. The following main decisions were made at the AGM: The income statement and the balance sheet for both the parent company and the group regarding the financial year 2021 were adopted by the AGM. The AGM decided that no dividend would be paid out for the financial year 2021. The members of the Board and the CEO were

Trelleborg exercises authorization to acquire own shares

The Board of Directors of Trelleborg has decided to exercise the authorization granted by the Annual General Meeting on April 27, 2022, to acquire own shares of series B.   Acquisition of shares will be carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 (”MAR”) and the Commission Delegated Regulation (EU) No 2016/1052 (the “Safe Harbour Regulation”). Acquisitions of shares will be managed by an investment firm or a credit institution that makes its trading decisions independently of Trelleborg with regard to the timing of the acquisition of shares in

ABS Supports McAllister’s Decarbonization with Greenhouse Gas Inventory and Sustainability Reporting

Image courtesy of McAllister. (NEW YORK) ABS is supporting McAllister on its sustainability journey with greenhouse gas inventory and sustainability reporting services for its fleet of more than 75 tugboats, crew boats and barges. ABS specialists worked with McAllister’s team to calculate its operational carbon intensity and benchmark the performance of its fleet, leading up to an Environmental, Societal and Governance (ESG) report. The team helped McAllister establish a transparent governance and stakeholder engagement strategy, identify material ESG factors and set short-

Press release from Trelleborg AB’s 2022 Annual General Meeting

Trelleborg AB held its 2022 Annual General Meeting today, April 27, 2022. In order to minimize the risk of spreading the coronavirus, the Meeting was held without the physical presence of shareholders who could only exercise their voting rights via postal voting.   Presentations by the Chairman of the Board, Hans Biörck, and the CEO, Peter Nilsson, will be available today on www.trelleborg.com.   Dividend The Meeting resolved in accordance with the board of directors’ proposal to pay a dividend in the amount of SEK 5.50 per share. The record date for the dividend was set as

Cantargia to present new clinical data on lead IL1RAP antibody nadunolimab over three sessions at ASCO 2022

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) will present three posters with new clinical data from the CANFOUR and CIRIFOUR trials on its most advanced program, nadunolimab, at the American Society of Clinical Oncology (ASCO) Annual Meeting 2022 to be held in Chicago on 3-7 June 2022. Two of the presentations will also be included in poster discussion sessions where select posters are highlighted. These focus on therapy of pancreatic cancer (PDAC) or non-small cell lung cancer (NSCLC) patients in the CANFOUR trial.“We are excited to communicate Cantargia’s clinical data updates at

Getinge to acquire FLUOPTICS, a technology leader in the area of Near Infrared Imaging

Getinge announces today an agreement to acquire 100% of the shares in FLUOPTICS SAS, a French based leader in fluorescence imaging as an aid to surgery. The acquisition will expand Getinge’s customer offering in clinical decision support by providing safe and improved operating efficiency.FLUOPTICS, based in Grenoble, France, was founded in 2009 and has since developed NIR imaging systems, consisting of a dedicated camera and the related software, to visualize the vascularization and other tissues by the use of a fluorescent marker or by using the natural autofluorescence of the tissues.

There are no items matching the current filter
There are no more items matching the current filter
Back to top